E-Mail
IMAGE: Brandon J. Henderson, Ph.D., an assistant professor of biomedical sciences at the Marshall University Joan C. Edwards School of Medicine, has been awarded a $1.86 million Research Project Grant (R01). view more
Credit: Marshall University Joan C. Edwards School of Medicine
HUNTINGTON, W.Va. - Brandon J. Henderson, Ph.D., an assistant professor of biomedical sciences at the Marshall University Joan C. Edwards School of Medicine, has been awarded a Research Project Grant (R01), one of the most competitive grants issued by the National Institutes of Health (NIH).
Henderson was awarded the $1.86 million five-year grant (R01DA050717) from the National Institute on Drug Abuse to study the neurobiological and neurophysiological changes that occur due to vaping nicotine in flavored products. Henderson s research team is working to better understand how electronic nicotine delivery systems, or vaping, alter neurobiology to trigger nicotine addiction in adolescent
UW studying low-nicotine cigarettes, which may be required by Biden administration
journaltimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from journaltimes.com Daily Mail and Mail on Sunday newspapers.
Achieve Reports Financial Results for Fourth Quarter and Year-End 2020 and Provides Corporate Update
newjerseytelegraph.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newjerseytelegraph.com Daily Mail and Mail on Sunday newspapers.
(2)
SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / March 11, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced fourth quarter and year-end 2020 financial results and provided an update on the cytisinicline clinical development program.
Recent Events & Highlights
Initiated the Phase 3 ORCA-2 clinical trial evaluating the efficacy and safety of 3 mg cytisinicline dosed 3 times daily compared to placebo in 750 adult smokers at 15 clinical sites in the United States
Presented data on smoker and e-cigarette user attitudes and perceptions on quitting at the Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting on February 24, 2021